The potential application of cyclo-oxygenase type 2 inhibitors to Alzheimer’s disease

Bibliography

• FELICIAN 0, SANDSON TA: Recent developments in the pathophysiology and pharmacotherapy of Alz-heimer's disease: part 1. Drugs Today (1997) 33:555–562.
   Web of Science ®Google Scholar
• HARDY J: The Alzheimer family of diseases: many eti-ologies, one pathogenesis? Proc. Natl. Acad. Sci. USA (1997) 94:2095–2097.
   PubMed Web of Science ®Google Scholar
• ST GEORGE-HYSLOP PH, CRAPPER MCLACHLAN DR, HAINES JL et al: Molecular genetic evidence for etio-logic heterogeneity of Alzheimer's disease. In: Hetero-geneity of Alzheimer's Disease. Boller F, Forette F, Khachaturia Z, Poncet M, Christen Y (Eds.), Springer-Verlag, Berlin, Germany (1992):88–95.
   Google Scholar
• AISEN PS, DAVIS KL: Inflammatory mechanisms in Alz-heimer's disease: implications for therapy. Am. J. Psy-chiat. (1994) 151:1105–1113.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, ROGERS J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurol-ogy (1992) 42:447–449.
   PubMed Web of Science ®Google Scholar
• ROGERS J, WEBSTER S, LUE LF et al: Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging (1996) 17:681–686.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, MCGEER EG: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Re-views (1995) 21:195–218.
   PubMed Web of Science ®Google Scholar
• ALZHEIMER A: über eine eigenartige Erkrankung der Hirnrinde. Zeitschrift far Psychiatrie (1906) 10:146–148.
   Google Scholar
• GLENNER GG, WONG CW: Alzheimer's disease: report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. (1984) 120:885–890.
   PubMed Web of Science ®Google Scholar
• JARRET JT, BERGER EP, LANSBURY PT: The carboxy ter-minus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 32:4693–4697.
   PubMed Web of Science ®Google Scholar
• OHTSUBO K, IZUMIYAMA N, SHIMADA H et al: Three-dimensional structure of Alzheimer's neuroflbrillary tangles of the aged human brain revealed by the quick-freeze, deep-etch and replica method. Acta Neu-ropathol. (1990) 79:480–485.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, ROGERS J, MCGEER EG: Neuroimmune mechanisms in Alzheimer's disease pathogenesis. Alz. Dis. Assoc. Disord. (1994) 8:149–158.
   PubMed Web of Science ®Google Scholar
• MATSUBASA E, HIRAI S, AMARI M et al: Alpha 1-antichymotripsin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. (1990) 28:561–567.
   PubMed Web of Science ®Google Scholar
• BAUER J, GANTER U, STRAUSS S et al: The participationof interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. (1992) 143:650–657.
   PubMedGoogle Scholar
• MATSUBASA E, HIRAI S, AMARI M et al.: Alpha 1-antichymotripsin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. (1990) 28:561–567.
   PubMed Web of Science ®Google Scholar
• BAUER J, GANTER U, STRAUSS S et al: The participationof interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. (1992) 143:650–657.
   PubMedGoogle Scholar
• MCGEER PL, AKIYAMA H, ITAGAKI S, MCGEER EG: Acti-vation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Letts. (1989) 107:341–346.
   PubMed Web of Science ®Google Scholar
• ROGERS J, COOPER NR, WEBSTER S et al.: Complementactivation by beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1992) 89:10016–10020.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, MCGEER EG: Complement proteins andcomplement inhibitors in Alzheimer's disease. Res. Im-munol. (1992) 143:621–624.
   Google Scholar
• VANDENABEELE P, FIERS W: Is amyloidogenesis duringAlzheimer's disease due to an IL-1/11-6 mediated "acute phase response" in the brain? Immunol. Today (1991) 12:217–219.
   Google Scholar
• GOLD GABER D, HARRIS HW, HLA T et al: Interleukin-1regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA (1989) 86:7606–7610.
   PubMed Web of Science ®Google Scholar
• WYSS-CORAY T, MASLIAH E, MALLORY M et al.: Amyloi-dogenic role of cytokine TGF-beta 1 in transgenic mice and in Alzheimer's disease. Nature (1997) 389:603–606.
   PubMed Web of Science ®Google Scholar
• ITAGAKI S, MCGEER PL, AKIYAMA H: Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's brain tissue. Neurosci. Letts. (1988) 91:259–264.
   PubMed Web of Science ®Google Scholar
• SOLERTE SB, FIORAVANTI M, SERVERGNINI S et al.: Exci-tatory pattern of gamma-interferon on natural killer cell activity in senile dementia of the Alzheimer type. Dementia Geriatr. Cogn. Disord. (1997) 8:308–313.
   PubMed Web of Science ®Google Scholar
• PAYAMI H, SCHELLENBERG GD, ZAREPARSI S et al.: Evi-dence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology (1997) 49:512–518.
   PubMed Web of Science ®Google Scholar
• SUBBARAO KV, RICHARDSON JS, ANG LC: Autopsy sam-ples of Alzheimer's cortex show increased peroxida-tion in vitro. J. Neurochem. (1990) 55:342–345.
   PubMed Web of Science ®Google Scholar
• SMITH CD, CARNEY JM, STARKE-REED PE et al: Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1991) 88:10540–10543.
   PubMed Web of Science ®Google Scholar
• PAPPOLLA MA, OMAR RA, KIM KS et al.: Immunohisto-chemical evidence of oxidative stress in Alzheimer's disease. Am. J. Pathol. (1992) 140:621–628.
   PubMed Web of Science ®Google Scholar
• LOO DT, COPANI A, PIKE CJ et al.: Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA (1993) 90:7951–7955.
   PubMed Web of Science ®Google Scholar
• MARK RJ, HENSLEY K, BUTTERFIELD DA et al.: Amyloid beta-peptide impairs ion-motive ATPase activities: evi-dence for a role in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. (1995) 15:6239–6249.
   PubMed Web of Science ®Google Scholar
• YANKNER BA, DUFFY LK, KIRSCHNER DA: Neurotrophic and neurotoxic effects of amyloid beta protein: rever-sal by tachykinin neuropeptides. Science (1990) 250:279–282.
   PubMed Web of Science ®Google Scholar
• YAN SD, CHEN X, FU J et al.: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 382:685–691.
   PubMed Web of Science ®Google Scholar
• HORI 0, BRETT J, SLATTERY T et al.: The receptor for ad-vance glycation end products (RAGE) is a cellular bind-ing site for amphoterin. J. Biol. Chem. (1995) 270:25752–25761.
   Google Scholar
• EL KHOURY J, HICKMAN SE, THOMAS CA et al.: Scaven-ger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature (1996) 382:716–719.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and anti-inflammatory agents as possible protective fac-tors for Alzheimer's disease: a review of 17 epidemiol-ogic studies. Neurology (1996) 47:425–432.
   PubMed Web of Science ®Google Scholar
• BREITNER JCS, GAU BA, WELSH KA, PLASSMAN BL et al.: Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology (1994) 44:227–232.
   PubMed Web of Science ®Google Scholar
• RICH JB, RASMUSSON DX, FOLSTEIN MF et al.: Nonsteroi-dal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 45:51–55.
   PubMed Web of Science ®Google Scholar
• SCHNABEL J: New Alzheimer's therapy suggested (re-search news). Science (1993) 260:1719–1720.
   PubMed Web of Science ®Google Scholar
• ANDERSEN K, LAUNER LJ, OTT A et al.: Do nonsteroidal anti-inflammatory drugs decrease the risk for Alz-heimer's disease? The Rotterdam study. Neurology (1995) 45:1441–1445.
   PubMed Web of Science ®Google Scholar
• STEWART WF, KAWAS C, CORRADA M, METTER EJ: Risk of Alzheimer's disease and duration of NSAID use. Neu-rology (1997) 48:626–632.
   Google Scholar
• ROGERS J, KIRBY LC, HEMPELMAN SR, BERRY DL et al.: Clinical trial of indomethacin in Alzheimer's disease. Neurology (1993) 43:1609–1611.
   PubMed Web of Science ®Google Scholar
• CORDER EH, SAUNDERS AM, STRITTMATTER WJ et al.:Gene dose of Apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Sci-ence (1993) 261:921–923.
   PubMed Web of Science ®Google Scholar
• PERICAK-VANCE MA, BASS MP, YAMAOKA LH et al: Com-plete genomic screen in late-onset familial Alz-heimer's disease. Evidence for a new locus on chromosome 12. JAMA (1997) 278:1237–1241.
   Google Scholar
• KAWAS C, RESNICK S, MORRISON A et al.: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease. The Baltimore Longi-tudinal Study of Aging. Neurology (1997) 48:1517–1521.
   Google Scholar
• STERN Y, GURLAND B, TATEMICHI TK eta].: Influence ofeducation and occupation on the incidence of Alz-heimer's disease. JAMA (1994) 271:1004–1010.
   Google Scholar
• VAN DUIJN CM, TANJA TA, HAAXMA R et al.: Head trauma and the risk of Alzheimer's disease. Am. J. Epidemic)]. (1992) 135:775–782.
   PubMed Web of Science ®Google Scholar
• YANKNER BA, DUFFY LK, KIRSCHNER DA: Neurotrophic and neurotoxic effects of amyloid beta protein: rever-sal by tachykinin neuropeptides. Science (1990) 250:279–282.
   PubMed Web of Science ®Google Scholar
• GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overexpress-ing V717F beta-amyloid precursor protein. Nature (1995) 373:523–527.
   PubMed Web of Science ®Google Scholar
• ARRIAGADA PV, GROWDON JH, HEDLEY-WHYTE T et al.: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 42:631–639.
   PubMed Web of Science ®Google Scholar
• TERRY RD: The pathogenesis of Alzheimer's disease: an alternative to the amyloid hypothesis. J. Neuropathol Exp. Neurol. (1996) 55:1023–1025.
   PubMed Web of Science ®Google Scholar
• MACKENZIE IRA: Antiinflammatory drugs in the treat-ment of Alzheimer's disease. J. RheumatoL (1996) 23:806–808.
   PubMed Web of Science ®Google Scholar
• FU JY, MASFERRER JL, SIEBERT K eta].: The induction andsuppression of prostaglandin H2 synthase (cyclooxy-genase) in human monocytes. J. Biol. Chem. (1990) 265:16737–16740.
   Google Scholar
• SEIBERT K, ZHANG Y, LEAHY K et al.: Pharmacologicaland biochemical demonstration of the role of cyclo-oxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA (1994) 91:12013–12017.
   PubMed Web of Science ®Google Scholar
• BREEDER CD, DEWITT D, KRAIG RP: Characterization ofinducible cyclooxygenase in rat brain. J. Comp. NeuroL (1995) 355:296–315.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, ZWEIFEL BS, SEIBERT K, NEEDLEMAN P:Selective regulation of cellular cyclooxygenase by dex-amethasone and endotoxin in mice. J. Clin. Invest. (1990) 86:1375–1379.
   PubMed Web of Science ®Google Scholar
• TOCCO G, FREIRE-MOAR J, SCHREIBER SS et al. Matura- tional regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alz- heimer's disease. Exp. Neurol. (1997) 144:339–349.
   PubMed Web of Science ®Google Scholar
• MIETTINEN S, FUSCO FR, YRJANHEIKKI J et al.: Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc. Natl. Acad. Sci. USA (1997) 94:6500–6505.
   PubMed Web of Science ®Google Scholar
• VAN RYN J, PAIRET M: Selective cyclooxygenase-2 inhi-hitors: pharmacology, clinical effects and therapeutic potential. Exp. Opin. Invest. Drugs (1997) 6:609–614.
   PubMedGoogle Scholar